Pzena Investment Management LLC Increases Position in United Therapeutics Co. (NASDAQ:UTHR)

Pzena Investment Management LLC raised its position in United Therapeutics Co. (NASDAQ:UTHRFree Report) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,022 shares of the biotechnology company’s stock after purchasing an additional 159 shares during the period. Pzena Investment Management LLC’s holdings in United Therapeutics were worth $445,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Blue Trust Inc. increased its position in shares of United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares during the last quarter. Formidable Asset Management LLC grew its position in shares of United Therapeutics by 1.5% in the 3rd quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 53 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in shares of United Therapeutics by 1.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock valued at $856,000 after buying an additional 61 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC grew its position in shares of United Therapeutics by 6.1% in the 3rd quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 73 shares during the last quarter. Finally, E Fund Management Co. Ltd. grew its position in shares of United Therapeutics by 3.9% in the 3rd quarter. E Fund Management Co. Ltd. now owns 2,032 shares of the biotechnology company’s stock valued at $459,000 after buying an additional 77 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total transaction of $77,285.00. Following the completion of the transaction, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Nilda Mesa sold 325 shares of United Therapeutics stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total transaction of $77,285.00. Following the completion of the sale, the director now directly owns 5,373 shares in the company, valued at $1,277,699.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christopher Patusky sold 1,680 shares of United Therapeutics stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $224.00, for a total transaction of $376,320.00. Following the sale, the director now owns 4 shares of the company’s stock, valued at $896. The disclosure for this sale can be found here. Insiders sold 155,208 shares of company stock worth $37,436,641 over the last 90 days. Company insiders own 12.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Oppenheimer increased their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Wedbush reaffirmed an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, May 2nd. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, SVB Leerink initiated coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective on the stock. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $309.44.

Read Our Latest Stock Analysis on UTHR

United Therapeutics Stock Performance

Shares of UTHR stock traded down $0.61 during mid-day trading on Thursday, hitting $275.83. The stock had a trading volume of 66,240 shares, compared to its average volume of 455,471. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $279.98. The firm has a market cap of $12.23 billion, a PE ratio of 12.93, a PEG ratio of 4.17 and a beta of 0.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The company’s 50-day simple moving average is $245.78 and its 200-day simple moving average is $233.38.

United Therapeutics (NASDAQ:UTHRGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. During the same quarter last year, the business earned $4.86 earnings per share. The business’s revenue for the quarter was up 33.7% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Co. will post 24.2 earnings per share for the current year.

United Therapeutics Company Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.